NCT00188084

Brief Summary

Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:

  1. 1.A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
  2. 2.The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2003

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2003

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2005

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

September 12, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
Last Updated

October 28, 2005

Status Verified

September 1, 2005

First QC Date

September 12, 2005

Last Update Submit

October 27, 2005

Conditions

Adult Acute Lymphoblastic Leukemia

Interventions

DNA IndexPROCEDURE
S-Phase%PROCEDURE
CD45 expressionPROCEDURE
P16 metabolic wayPROCEDURE

Eligibility Criteria

Age15 Years - 59 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • All GRAALL 2003 and 2005 enrolled patients with available frozen blast cells

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CRLCC Centre Paul Papin

Angers, 49933, France

RECRUITING

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

PloidiesS Phase

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Genetic PhenomenaDNA ReplicationBiochemical PhenomenaChemical PhenomenaInterphaseCell CycleCell Physiological Phenomena

Study Officials

  • Laurence M Baranger, MD

    University Hospital, Angers

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Agnès F CHASSEVENT, PhD

CONTACT

33-(0)2-41-35-27-00a.chassevent@unimedia.fr

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 16, 2005

Study Start

November 1, 2003

Study Completion

September 1, 2005

Last Updated

October 28, 2005

Record last verified: 2005-09

Locations

FR(1)